Movement Alert｜Akeso Falls 3.16% in Regular Trading, Post-ASCO Profit-Taking Continues as Stock Nears 52-Week Low

Market Focus10:30

On June 26, Akeso fell 3.16% in regular trading, trading at HK$82.75/share with turnover of HK$382 million, as the stock approached its 52-week low of HK$80.20.

The decline reflects continued selling pressure following the company's ASCO presentation of positive overall survival data from the HARMONi-6 trial for ivonescimab. Despite the landmark clinical results demonstrating a 34% reduction in death risk for squamous NSCLC patients, the stock has fallen over 30% from its post-data high as investors locked in gains. The board's approved HK$200 million share repurchase plan and management's planned purchase of up to HK$50 million in shares have yet to stem the selling.

The broader biotech sector remained weak, with Innovent Biologics down 1.58%, Remegen down 1.28%, and BeiGene down 0.42%, reflecting persistent sector-wide headwinds that compounded stock-specific profit-taking pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192481329?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192481329","market":"us","top_or_hot":-1,"title":"Movement Alert｜Akeso Falls 3.16% in Regular Trading, Post-ASCO Profit-Taking Continues as Stock Nears 52-Week Low","media":"Market Focus","content":"<p><p>On June 26, Akeso fell 3.16% in regular trading, trading at HK$82.75/share with turnover of HK$382 million, as the stock approached its 52-week low of HK$80.20.</p><p>The decline reflects continued selling pressure following the company's ASCO presentation of positive overall survival data from the HARMONi-6 trial for ivonescimab. Despite the landmark clinical results demonstrating a 34% reduction in death risk for squamous NSCLC patients, the stock has fallen over 30% from its post-data high as investors locked in gains. The board's approved HK$200 million share repurchase plan and management's planned purchase of up to HK$50 million in shares have yet to stem the selling.</p><p>The broader biotech sector remained weak, with Innovent Biologics down 1.58%, Remegen down 1.28%, and BeiGene down 0.42%, reflecting persistent sector-wide headwinds that compounded stock-specific profit-taking pressure.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Falls 3.16% in Regular Trading, Post-ASCO Profit-Taking Continues as Stock Nears 52-Week Low</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Falls 3.16% in Regular Trading, Post-ASCO Profit-Taking Continues as Stock Nears 52-Week Low\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Akeso fell 3.16% in regular trading, trading at HK$82.75/share with turnover of HK$382 million, as the stock approached its 52-week low of HK$80.20.</p><p>The decline reflects continued selling pressure following the company's ASCO presentation of positive overall survival data from the HARMONi-6 trial for ivonescimab. Despite the landmark clinical results demonstrating a 34% reduction in death risk for squamous NSCLC patients, the stock has fallen over 30% from its post-data high as investors locked in gains. The board's approved HK$200 million share repurchase plan and management's planned purchase of up to HK$50 million in shares have yet to stem the selling.</p><p>The broader biotech sector remained weak, with Innovent Biologics down 1.58%, Remegen down 1.28%, and BeiGene down 0.42%, reflecting persistent sector-wide headwinds that compounded stock-specific profit-taking pressure.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1192481329","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192481329","pubTimestamp":1782441026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Akeso fell 3.16% in regular trading, trading at HK$82.75/share with turnover of HK$382 million, as the stock approached its 52-week low of HK$80.20.The decline reflects continued selling...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势提示|康方生物常规交易下跌3.16%，ASCO后获利了结持续，股价接近52周低点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 26, Akeso fell 3.16% in regular trading, trading at HK$82.75/share with turnover of HK$382 million, as the stock approached its 52-week low of HK$80.20.The decline reflects continued selling pressure following the company's ASCO presentation of positive overall survival data from the HARMONi-6 trial for ivonescimab. Despite the landmark clinical results demonstrating a 34% reduction in death risk for squamous NSCLC patients, the stock has fallen over 30% from its post-data high as investors locked in gains. The board's approved HK$200 million share repurchase plan and management's planned purchase of up to HK$50 million in shares have yet to stem the selling.The broader biotech sector remained weak, with Innovent Biologics down 1.58%, Remegen down 1.28%, and BeiGene down 0.42%, reflecting persistent sector-wide headwinds that compounded stock-specific profit-taking pressure.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192481329","isCrawlerRequest":true}